TransIT®-In Vivo Gene Delivery System

A nontoxic, polymer based in vivo delivery system for the delivery of DNA to the livers of laboratory mice using hydrodynamic tail vein injection

• Polymer Mediated DNA Delivery—Achieve higher levels of gene expression compared to polylysine and PEI methods.
• Versatile Platform—Suitable for DNA delivery using the hydrodynamic tail vein injection to the mouse strain of your choice.
• Low Toxicity—Normal mouse activity levels are restored within minutes after the injection.

Kit Components:

Each kit contains a Polymer Solution and 10X Delivery Solution.

Data

Figure 1: Beta-Gal Expression in Mouse Liver is Achieved Using the TransIT®-In Vivo Gene Delivery System.
Figure 2: The TransIT-In Vivo Gene Delivery System Leads to Luciferase Expression in a Variety of Organs.
Figure 3: Quantitative Comparison of Luciferase Reporter Activity in Mouse Liver Following In Vivo Gene Delivery.

Figure 1. Beta-Galactosidase Expression in Mouse Liver is Achieved Using the TransIT-In Vivo Gene Delivery System. A B-Gal expression vector was complexed with the TransIT-In Vivo Polymer Solution and delivered to mice using the hydrodynamic tail vein injection. Twenty-four hours post-injection, liver sections were stained using the Beta-Gal Staining Kit. NOTE: Following gene delivery via a tail vein injection, the highest level of transgene expression is found in the liver, with reduced levels of expression found in the spleen, lung, heart and kidneys.

Figure 2. The TransIT-In Vivo Gene Delivery System Leads to Luciferase Expression in a Variety of Organs. A luciferase expression vector was complexed with TransIT-In Vivo Polymer and delivered to mice using the hydrodynamic tail vein injection. Luciferase expression was measured twenty-four hours after injection.

Figure 3. Quantitative Comparison of Luciferase Reporter Activity in Mouse Liver Following In Vivo Gene Delivery. A luciferase expression vector was complexed with either the TransIT-In Vivo Polymer Solution or the indicated agent and delivered to mice via tail-vein injection. Luciferase expression was quantified by assaying the total amount of luciferase produced in mouse liver.

NOTE: In vivo hydrodynamic delivery of non-viral nucleic acids is covered by worldwide patents and patent applications of Mirus Bio Corporation, including U.S. Patent 6,627,616, U.S. Patent 6,379,966, and related filings worldwide. Purchase of this product does not provide a license to this delivery technology, which is required for all research and commercial uses by for-profit entities. To inquire about a license, please contact Mirus Bio Corporation.